Ethanol extract of Evodia lepta Merr. ameliorates cognitive impairment through inhibiting NLRP3 inflammasome in scopolamine-treated mice

Rui-Dan Hu, Wenli Zhu, Weiyao Lin, Yuhui Qiu, Guangliang Wu, Xiao-Ying Ding, Zhenkun Yang, Qian Feng, Rongrong Zhang, Lijun Qiao, Yefeng Cai, Shijie ZhangAging 2024 · DOI

This research paper, published in AGING, investigates the neuroprotective potential of Evodia lepta Merr. (EL), a traditional Chinese medicinal plant, against cognitive decline. Using a scopolamine-induced mouse model of dementia, the researchers demonstrate that an ethanol extract of EL significantly improves memory and learning by restoring cholinergic function and, crucially, inhibiting the NLRP3 inflammasome pathway.

TL;DR

Researchers found that an ethanol extract of the medicinal plant Evodia lepta reverses scopolamine-induced memory loss in mice. The extract works through a multi-pronged mechanism: restoring neurotransmitter levels, boosting synaptic plasticity, and suppressing the NLRP3 inflammasome—a key driver of neuroinflammation and cell death.

What Problem Does This Paper Address?

Dementia remains a global health challenge with limited therapeutic options. While the "cholinergic hypothesis"—the idea that memory loss is driven by a lack of the neurotransmitter acetylcholine (ACh)—has guided drug development for decades, it doesn't tell the whole story. Modern research points to neuroinflammation and oxidative stress as critical accelerators of the disease.

The NLRP3 inflammasome is a protein complex that, when activated, triggers a cascade of inflammatory cytokines and a form of programmed cell death called pyroptosis. While Evodia lepta was known to have neuroprotective properties, its specific effect on the NLRP3 pathway in the context of dementia was unknown. This paper seeks to bridge that gap, exploring if EL can act as a multi-target therapeutic agent.

Methods

The study followed a rigorous pharmacological workflow:

  1. Chemical Profiling: The researchers used HPLC-Q-TOF HRMS (High-Performance Liquid Chromatography coupled with Quadrupole Time-of-Flight High-Resolution Mass Spectrometry) to identify the primary bioactive components in the EL ethanol extract.
  2. Animal Modeling: Male C57BL/6 mice were treated with scopolamine to induce cognitive impairment.
  3. Treatment Protocol: Mice received either a low dose (10 mg/kg) or high dose (20 mg/kg) of EL extract, or Donepezil (a standard dementia drug) as a positive control, via gavage for 14 days.
  4. Behavioral Assays: Cognitive function was assessed using the Morris Water Maze (spatial memory), Object Recognition Task (recognition memory), and Open Field Test (anxiety and exploration).
  5. Molecular Analysis: After behavioral testing, brain tissues (specifically the hippocampus) were analyzed via Western blot and immunofluorescence to measure protein expressions related to synaptic plasticity (PSD95, BDNF), apoptosis (Bax, Bcl-2), and the NLRP3 inflammasome.

Datasets

As a biological study, the "datasets" consist of experimental results from specific cohorts:

  • Experimental Groups: Control, Scopolamine model, EL-Low (10 mg/kg), EL-High (20 mg/kg), and Donepezil (5 mg/kg).
  • Chemical Library: A profile of 14 major compounds identified within the EL extract, including various coumarins and alkaloids (e.g., skimmianine, oroxylin A, and scopoletin).

Key Insights and Ideas

  • The NLRP3 Connection: The most significant finding is that EL extract directly inhibits the NLRP3 inflammasome and its downstream effector, Cleaved Caspase-1. This suggests EL doesn't just mask symptoms but actively reduces the inflammatory environment that kills neurons.
  • Restoring the "Brakes" and "Gas": EL extract restored the cholinergic system by increasing Choline acetyltransferase (ChAT) activity (the "gas" that makes ACh) and decreasing Acetylcholinesterase (AChE) activity (the "brakes" that break it down).
  • Synaptic Reinforcement: The extract increased levels of BDNF (a growth factor for neurons) and PSD95 (a protein essential for synaptic strength). This implies the treatment helps maintain the physical infrastructure of memory.
  • Anti-Apoptotic Effects: By shifting the ratio of Bcl-2 (anti-death) to Bax (pro-death) proteins, the extract effectively shielded hippocampal neurons from programmed cell death.

Key Results

  • Behavioral Recovery: In the Morris Water Maze, mice treated with EL extract showed significantly shorter escape latencies and more frequent crossings of the target platform area compared to the scopolamine-only group.
  • Biochemical Restoration: EL treatment (20 mg/kg) nearly restored ACh levels to those of the control group and significantly reduced MDA (a marker of oxidative stress) while boosting SOD (an antioxidant enzyme).
  • Inflammasome Suppression: Western blots showed a marked decrease in NLRP3 and Cleaved Caspase-1 expression in the EL-treated groups, confirming the anti-inflammatory mechanism.

Limitations and Future Work

While promising, the study has a few limitations:

  • Acute vs. Chronic: The scopolamine model is an "acute" model of memory loss. It does not perfectly replicate the slow, progressive pathology of Alzheimer’s Disease, such as amyloid-beta plaque buildup.
  • The "Magic Bullet" Problem: The extract contains at least 14 major compounds. The authors acknowledge that further research is needed to identify which specific compound (or synergistic combination) is responsible for the NLRP3 inhibition.
  • Clinical Translation: As with all mouse studies, the metabolic differences between rodents and humans mean that the dosage and efficacy may not translate directly to clinical settings.

Future research will likely focus on isolating these 14 compounds to find the most potent individual lead for drug development.

Summary updated

Abstract

<i>Evodia lepta</i> Merr. (Evodia lepta) is a well-known traditional Chinese medicine, which has been widely used in herbal tea. We previously reported that the coumarin compounds from the root of Evodia lepta exhibited neuroprotective effects. However, whether Evodia lepta could inhibit NLRP3 inflammasome in dementia was still unknown. In this study, the components of the Evodia lepta extract were identified by HPLC-Q-TOF HRMS. We employed a scopolamine-treated mouse model. Evodia lepta extract (10 or 20 mg/kg) and donepezil were treated by gavage once a day for 14 consecutive days. Following the behavioral tests, oxidative stress levels were measured. Then, Western blot and immunofluorescence analysis were used to evaluate the expressions of NLRP3 inflammasome. 14 major components of the Evodia lepta extract were identified by HPLC-Q-TOF HRMS. The results of Morris water maze, object recognition task and open field test indicated that Evodia lepta extract could ameliorate cognitive impairment in scopolamine-treated mice. Evodia lepta extract improved cholinergic system. Moreover, Evodia lepta extract improved the expressions of PSD95 and BDNF. Evodia lepta extract suppressed neuronal oxidative stress and apoptosis. In addition, Evodia lepta extract inhibited NLRP3 inflammasome in the hippocampus of scopolamine-treated mice. Evodia lepta extract could protect against cognitive impairment by inhibiting NLRP3 inflammasome in scopolamine-treated mice.
BibTeX
@inproceedings{hu2024ethanol,
  author = {Rui-Dan Hu and Wenli Zhu and Weiyao Lin and Yuhui Qiu and Guangliang Wu and Xiao-Ying Ding and Zhenkun Yang and Qian Feng and Rongrong Zhang and Lijun Qiao and Yefeng Cai and Shijie Zhang},
  title = {{Ethanol extract of Evodia lepta Merr. ameliorates cognitive impairment through inhibiting NLRP3 inflammasome in scopolamine-treated mice}},
  booktitle = {Aging},
  year = {2024},
  doi = {10.18632/aging.205486},
}
Figure